专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2022049302A1 METHOD OF PERFORMING ULTRASOUND MEASUREMENTS ON A HUMAN OR ANIMAL BODY 审中-公开
公开(公告)号：WO2022049302A1
公开(公告)日：2022-03-10
申请号：PCT/EP2021/074559
申请日：2021-09-07
申请人： RIGSHOSPITALET
发明人： SVENDSEN, Morten, Bo, Søndergaaard , GHULAM, Qasam, Mohammed , EIBERG, Jonas
IPC分类号： A61B8/00 , A61B8/08 , G01N29/28
摘要： The invention relates to ultrasound measurements on a human or animal body (1). An ultrasound compatible and compressible elastic element (4) is interpositioned between a tissue surface (5) of the body and the ultrasound probe during the measurements. At least one ultrasound acquisition is obtained which includes a first region (6) representing the compression of the elastic element being compressed by pressure applied with the ultrasound probe and a second region (7) representing at least a part of the body under investigation. The compression of the elastic element is measured, and based on this compression and a known correlation between elastic element compression and applied pressure, it is possible to determine the pressure applied with the ultrasound transducer. Hereby it is possible to obtain results that are more reliable than what is obtained by known methods.

2. 发明申请

WO2021069542A1 ZAFIRLUKAST DERIVATIVES FOR USE AS CONTRACEPTIVE AGENTS 审中-公开
公开(公告)号：WO2021069542A1
公开(公告)日：2021-04-15
申请号：PCT/EP2020/078205
申请日：2020-10-08
申请人： RIGSHOSPITALET
发明人： REHFELD, Anders
IPC分类号： A61K31/404 , A61K31/56 , A61P15/06 , C07D209/24
摘要： The present invention concerns compounds and their use in contraception. These compounds are derivatives of zafirlukast and have been found to inhibit CatSper in human sperm cells in low concentrations.

3. 发明申请

WO2020165404A1 STEM CELL THERAPY FOR LACRIMAL GLAND DYSFUNCTION 审中-公开
公开(公告)号：WO2020165404A1
公开(公告)日：2020-08-20
申请号：PCT/EP2020/053876
申请日：2020-02-14
申请人： RIGSHOSPITALET , KØBENHAVNS UNIVERSITET
发明人： MØLLER-HANSEN, Michael , HEEGAARD, Steffen , LARSEN, Ann-Cathrine
IPC分类号： A61K35/12 , A61P27/02
摘要： Described herein are compositions comprising allogeneic adipose-derived stem cells and their use in treating or preventing lacrimal and/or meibomian gland dysfunction, e.g., in dry eye diseases, such as aqueous-deficient dry eye disease.

4. 发明申请

WO2019224393A1 FENOFIBRATE FOR REDUCING HYPOGLYCEMIA IN TYPE 1 DIABETES/LADA 审中-公开
公开(公告)号：WO2019224393A1
公开(公告)日：2019-11-28
申请号：PCT/EP2019/063620
申请日：2019-05-27
申请人： UNIVERSITY OF COPENHAGEN , RIGSHOSPITALET
发明人： BUSCHARD, Karsten , HOLM, Laurits Juulskov , HAUPT-JØRGENSEN, Martin
IPC分类号： A61K31/21 , A23L33/00 , A61P3/08 , A61K9/00
摘要： The present invention relates to compositions comprising Fenofibrate for use in the treatment, prophylaxis and/or prevention of hypoglycaemia in type 1 diabetes or other related diseases in humans. This treatment, prophylaxis and/or prevention is particularly relevant for subjects that are genetically predisposed to these diseases. The daily dose ranges from 1-100 mg/kg bodyweight per day.

5. 发明申请

WO2018178386A1 TARGETED MICROBUBBLES FOR DETECTION OF GLYCOCALYX 审中-公开
公开(公告)号：WO2018178386A1
公开(公告)日：2018-10-04
申请号：PCT/EP2018/058409
申请日：2018-04-03
申请人： RIGSHOSPITALET , UNIVERSITY OF COPENHAGEN
发明人： HEMPEL, Casper , NIELSEN, Lars, Bo , SILLESEN, Henrik
IPC分类号： C07K7/06 , A61K49/22
CPC分类号： C07K7/06 , A61K49/221 , A61K49/223
摘要： The present invention relates to a method for in vivo detection of the loss and/or presence of endothelial glycocalyx by using labelled microbubbles and ultrasound. The microbubbles are labelled with peptides via a lipid recognising specific components of the glycocalyx.

6. 发明申请

WO2016150448A1 BALLOON-TIPPED CATHETER FOR CONTINUOUS NERVE BLOCKS 审中-公开
标题翻译：用于连续神经阻滞的气囊导管
公开(公告)号：WO2016150448A1
公开(公告)日：2016-09-29
申请号：PCT/DK2016/050089
申请日：2016-03-22
申请人： RIGSHOSPITALET COPENHAGEN UNIVERSITY HOSPITAL
发明人： HESSELBJERG, Lars
IPC分类号： A61M25/00 , A61M19/00 , A61M29/02 , A61M25/06
CPC分类号： A61M25/0074 , A61M19/00 , A61M25/0075 , A61M25/065 , A61M25/10 , A61M29/02 , A61M2025/105
摘要： The invention relates to a catheter (1) for administering anaesthetics to a peripheral nerve site in a patient. The catheter (1) comprises a hollow, flexible catheter tube (2) having a first inner lumen (3) extending along a longitudinal axis of the catheter tube (2) from a proximal end (4) to a distal end (5) where a balloon (6) is arranged. The balloon (6) is adapted to be inflated from a collapsed state to an inflated state by a fluid fed through the catheter tube (2) into an inner cavity (7) of the balloon (6). The inflated balloon (6) is used to ensure that the distal end of the catheter (1) stays at the desired position at the peripheral nerve site. The catheter (1) may comprise a second lumen (10), so that the balloon (6) is inflated via one lumen and the anaesthetics is administered via the other lumen. The invention further relates to a needle-catheter kit and for a method of administering anaesthetics by use of such a catheter.
摘要翻译：本发明涉及一种用于向患者的周围神经部位施用麻醉剂的导管（1）。导管（1）包括中空的柔性导管（2），其具有沿着导管（2）的纵向轴线从近端（4）延伸到远端（5）的第一内腔（3）设置气球（6）。气球（6）适于通过通过导管（2）供给到气囊（6）的内腔（7）中的流体从收缩状态膨胀至膨胀状态。充气气球（6）用于确保导管（1）的远端停留在周围神经部位的期望位置。导管（1）可以包括第二腔（10），使得球囊（6）经由一个腔膨胀，并且麻醉剂经由另一个内腔施用。本发明还涉及一种针导管试剂盒以及使用这种导管给药麻醉药的方法。

7. 发明申请

WO2015144184A8 USE OF TIMP-1 AS A BIOMARKER IN THE EGF-RECEPTOR INHIBITOR TREATMENT OF METASTATIC COLORECTAL CANCER 审中-公开
公开(公告)号：WO2015144184A8
公开(公告)日：2015-10-01
申请号：PCT/DK2015/050069
申请日：2015-03-26
申请人： UNIVERSITY OF COPENHAGEN , RIGSHOSPITALET
发明人： BRÜNNER, Nils Aage , MOREIRA, José , CHRISTENSEN, Ib Jarle , TARPGAARD, Line Schmidt , PFEIFFER, Per
IPC分类号： G01N33/574
摘要： The present invention concerns the provision of biomarkers, in particular, TIMP-1 and RAS as biomarkers for the selection of patients in the treatment and prognosis of cancer, such as e.g. metastatic colorectal cancer (mCRC). The present invention also provides methods of patient selection, patient prognosis and methods of treatment of patients based on TIMP-1 levels in the blood, plasma or tumor tissue and the absence or presence of mutations in RAS, in particular KRAS, who are likely to benefit from treatment with an EGFR inhibitor alone or in combination with at least one chemotherapeutic agent. The present invention also provides for a method of treatment of m CRC in patients, which have been identified by the inventive method using the biomarker TIMP-1 and KRAS, who are likely to benefit from the treatment with the EGFR inhibitor cetuximab and at least one chemotherapeutic agent.

8. 发明申请

WO2015018421A1 ANTIBODIES, COMPOUNDS AND DERIVATIVES THEREOF FOR USE IN THE TREATMENT OF MALE INFERTILITY 审中-公开
标题翻译：用于治疗男性感染的抗体，化合物及其衍生物
公开(公告)号：WO2015018421A1
公开(公告)日：2015-02-12
申请号：PCT/DK2014/050235
申请日：2014-08-04
申请人： RIGSHOSPITALET COPENHAGEN UNIVERSITY HOSPITAL
发明人： JENSEN, Martin Blomberg
IPC分类号： A61K38/00 , A61K39/395 , C07K16/28 , A61P15/00
CPC分类号： C07K16/2875 , A61K38/1793 , A61K39/395 , A61K2039/505 , C07K2317/21 , C07K2317/76
摘要： The present invention relates to antagonists or inhibitors, which bind selectively to RANKL/OPGbp and regulate the interaction between RANKL/OPGbp and RANK/OPG.In particular, the present invention relates to an antibody or antigen binding domain, fragment or derivative thereof,immunoreactive with a RANKL/OPGbppeptidefor use in the treatment, prevention or alleviation of male infertility or reduced male fertility such as oligospermia or azospermia.
摘要翻译：本发明涉及与RANKL / OPGbp选择性结合并调节RANKL / OPGbp和RANK / OPG之间的相互作用的拮抗剂或抑制剂。特别地，本发明涉及抗体或抗原结合结构域，其片段或衍生物，免疫反应性与RANKL / OPGb肽用于治疗，预防或减轻男性不育症或降低的男性生育力，如精子减少或精子症。

9. 发明申请

WO2013143548A1 COMPOUNDS CAPABLE OF MODULATING/PRESERVING ENDOTHELIAL INTEGRITY FOR USE IN PREVENTION OR TREATMENT OF ACUTE TRAUMATIC COAGULOPATHY AND RESUSCITATED CARDIAC ARREST 审中-公开
标题翻译：可用于调节/保留内皮内镜完整性的化合物，用于预防或治疗急性脑血管病和恢复心脏病的ARREST
公开(公告)号：WO2013143548A1
公开(公告)日：2013-10-03
申请号：PCT/DK2013/050090
申请日：2013-03-26
申请人： RIGSHOSPITALET
发明人： JOHANSSON, Pär , OSTROWSKI, Sisse Rye
IPC分类号： G01N33/58 , G01N33/68 , A61K31/519 , A61K31/52 , A61K31/557
CPC分类号： A61K31/5585 , A61K31/519 , A61K31/52 , A61K31/557 , A61K31/5578 , A61K45/06 , G01N33/6893 , G01N33/86 , G01N2333/4722 , G01N2333/705 , G01N2800/224
摘要： The present invention relates to novel uses of compounds that protect the endothelium, particularly prostacyclin and variants and derivatives thereof in the treatment or prevention of acute traumatic coagulopathy (ATC) and of patients resuscitating from cardiac arrest. The invention also relates to a method of identifying individuals at risk of developing ATC.
摘要翻译：本发明涉及保护内皮，特别是前列环素及其变体和衍生物的治疗或预防急性创伤性凝血病（ATC）的化合物和由心脏骤停复苏的患者的新用途。本发明还涉及一种识别处于发展ATC风险的个体的方法。

10. 发明申请

WO2011079846A2 MRNA CLASSIFICATION OF THYROID FOLLICULAR NEOPLASIA 审中-公开
标题翻译：甲状腺分枝杆菌MRNA分类
公开(公告)号：WO2011079846A2
公开(公告)日：2011-07-07
申请号：PCT/DK2010/050358
申请日：2010-12-23
申请人： RIGSHOSPITALET , HERLEV HOSPITAL , ROSSING, Maria , NIELSEN, Finn Cilius , BENNEDBÆK, Finn Noe , BORUP-HELWEG-LARSEN, Rehannah Holga Andrea
发明人： ROSSING, Maria , NIELSEN, Finn Cilius , BENNEDBÆK, Finn Noe , BORUP-HELWEG-LARSEN, Rehannah Holga Andrea
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/112 , C12Q2600/158
摘要： The present invention relates to molecular classifiers based on specific m RNA expression patterns which distinguish the malignant and benign subtypes of thyroid follicular neoplasia; follicular thyroid carcinoma and follicular thyroid adenoma. The invention further relates to methods for diagnosing thyroid follicular neoplasia in samples from thyroid nodules to reduce the number of diagnostic operations and expediting surgery for individuals with a malignant nodule.
摘要翻译：本发明涉及基于特异性m RNA表达模式的分子分类器，其区分甲状腺滤泡瘤形成的恶性和良性亚型; 滤泡性甲状腺癌和滤泡性甲状腺腺瘤。本发明还涉及用于诊断来自甲状腺结节的样品中的甲状腺滤泡瘤形成的方法，以减少诊断操作的数量并加速具有恶性结节的个体的手术。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式